I have worked in Pharma and Biotech for over 20 years in Europe and the United States. In 15 years at Novo Nordisk I focused on biotherapeutics in the cardiometabolic space with an increasing level of people and project responsibility. I was fortunate to be a key part of 13 projects that transitioned from discovery to development and was a part of bringing semaglutide to the market for the treatment of diabetes and obesity (Ozempic, Rybelsus, Wegovy). Additionally I worked on multiple projects that focused on peptide and protein therapeutics including unimolecular multi-agonists, PK Extension, fusion proteins, tissue targeting, orally-available peptides and strategies for passage of large molecules across the blood-brain barrier. More recently I led the early discovery efforts at Catalyst Biosciences to progress protein degradation strategies to target diseases of the complement system. The success of our efforts led to our assets being sold recently to Vertex Pharmaceuticals.
Structure: 4ZGM - semaglutide in complex with extracellular domain of hGLP-1R
